STRIKE - Treating Patients With Early Axial Spondyloarthritis to Target - a 1 Year Randomized Controlled Study Taking an Intense Treatment Approach Versus Routine Treatment

Status: Discontinued

Phase of Trial: Phase IV

Latest Information Update: 06 Nov 2021

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Adalimumab (Primary) ; Nonsteroidal anti-inflammatories
Indications Ankylosing spondylitis; Non-radiographic axial spondyloarthritis
Focus Therapeutic Use
Acronyms STRIKE
Sponsors AbbVie; AbbVie Germany

05 Jan 2018 Status changed from active, no longer recruiting to completed.
05 Nov 2017 Planned End Date changed from 10 Apr 2020 to 31 Jan 2018.
05 Nov 2017 Planned primary completion date changed from 13 Sep 2019 to 31 Jan 2018.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com